Clinical Trials Logo

Clinical Trial Summary

The purpose of this study is to evaluate the pharmacokinetics, safety and tolerability of CKD-355.


Clinical Trial Description

An open-label, randomized, multiple-dosing parallel study to evaluate the pharmacokinetics, safety and tolerability of CKD-355 with D797 and D324 in healthy subjects ;


Study Design


Related Conditions & MeSH terms


NCT number NCT03802162
Study type Interventional
Source Chong Kun Dang Pharmaceutical
Contact
Status Completed
Phase Phase 1
Start date February 15, 2019
Completion date August 31, 2019

See also
  Status Clinical Trial Phase
Terminated NCT02503501 - Intranasal Glulisine in Amnestic Mild Cognitive Impairment and Probable Mild Alzheimer's Disease Phase 2
Recruiting NCT02854033 - Alzheimer's Disease Neuroimaging Initiative 3 (ADNI3)
Completed NCT02593318 - Trial of Oxaloacetate in Alzheimer's Disease (TOAD) Phase 1
Completed NCT02681172 - Impact of FBB PET Amyloid Imaging in Change of Diagnosis in Patients With AD Phase 4
Completed NCT02264899 - MEMENTO-VAScular COmponents of Dementia N/A
Completed NCT02531360 - Evaluation of [18F]MNI-815 as a Potential PET Radioligand for Imaging Tau Protein in the Brain of Patients With Tauopathies Phase 0
Recruiting NCT04570761 - Effects of Auditory Brain Stimulation by "Pink Noise" on Memory Capacities in Alzheimer's Disease: Proof of Concept Study N/A
Not yet recruiting NCT05592678 - δ in Dementia Clinical Trials Phase 2/Phase 3
Not yet recruiting NCT05558709 - Social-cognitive Functioning: Validation of a New Neuropsychological Test N/A
Recruiting NCT05059158 - Amyloid-β Clearance Mechanisms in Alzheimer's Disease
Recruiting NCT02832921 - Cognitive-motor Intervention Using Virtual Reality for Middle-aged Individuals at High Dementia Risk N/A
Completed NCT02370524 - Quantitative Evaluation of [18F]T807 as a Potential PET Radioligand for Imaging Tau in Patients With Alzheimer's Disease Phase 1
Completed NCT01780519 - The Cognitive Effects of Lorazepam in Healthy Older Individuals With TOMM40 Variable-length Polymorphisms Phase 1
Completed NCT02103894 - Evaluation of [18F]MNI-777 PET as a Marker of Tau Pathology in Subjects With Tauopathies Compared to Healthy Subjects Phase 1
Completed NCT01231971 - Alzheimer's Disease Neuroimaging Initiative 2
Recruiting NCT05291234 - A Study to Assess Safety of ABBV-916 and How Intravenous ABBV-916 Moves Through Body and Affects Brain Amyloid Plaque Clearance in Adult Participants (Aged 50-90 Years) With Early Alzheimer's Disease Phase 2
Active, not recruiting NCT05771428 - Study to Assess Adverse Events, Change in Disease Activity and How Oral ABBV-552 Capsules Moves Through the Body of Participants Aged 50 to 90 Years With Mild Alzheimer's Disease Phase 2
Recruiting NCT06114745 - A Trial of SHR-1707 Infusion in Patients With Mild Cognitive Impairment Due to Alzheimer's Disease and Mild Alzheimer's Disease Phase 1